A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 392 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... June 23, 2021 FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma August 24, 2021 ΚΑΡΚΙΝΟΣ ΕΝΔΟΜΗΤΡΙΟΥ February 10, 2019 FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC February 5, 2021 Load more HOT NEWS News digest – Genetic links to male breast cancer, bowel cancer... EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... EMA Recommends Extension of Therapeutic Indications for Osimertinib EMA Recommends Granting a Marketing Authorisation for Ivosidenib
